$LOAN

Manhattan Bridge Capital (NASDAQ:LOAN) Share Price Passes Below 200

Manhattan Bridge Capital (NASDAQ:LOAN) shares fell below their 200-day moving average during Wednesday trading, dipping to $4.18 and last trading at $4.23 versus a 200-day average of $4.52. Weiss Ratings downgraded LOAN from “hold (c)” to “hold (c-)” on May 11. The company reported Q1 EPS of $0.11 (vs. $0.12) and revenue of $2.07M (vs. $2.18M), and declared a $0.11 quarterly dividend payable July 15.

Original reporting
Published May 28, 2026, 9:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 28, 2026, 9:29 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Manhattan Bridge Capital (NASDAQ:LOAN) Share Price Passes Below 200 — source image
Decision brief

The 30-second read

$LOANBearishMed
01

Why it matters

Traders may treat the 200-day moving average breach as a momentum/positioning signal while the downgrade adds incremental bearish sentiment; dividend timing could partially offset downside for yield-seekers.

02

Market read

Company-specific technical weakness plus a recent rating downgrade creates a near-term trading catalyst for LOAN, even without fresh earnings/guidance.

03

What to watch

The article highlights a high dividend yield and upcoming payment date; some income-focused buyers may support the stock despite technical weakness.

Relevance 8/10Novelty 6/10Timing: during Wednesday trading (below 200-day moving average)

Background

Manhattan Bridge Capital (LOAN) is a small-cap BDC providing bridge loans, secured debt, and mezzanine financing to SMBs; the article focuses on a technical break and an analyst downgrade.

Company-level read

Ticker impact

$LOANBearishMedium confidence
Context

LOAN traded below its 200-day moving average and received a May 11 downgrade from Weiss Ratings, reinforcing near-term downside risk.

Expected impact

Bias toward further underperformance/volatility until price reclaims the 200-day area or new fundamentals emerge.

Evidence & confidence

The article provides a concrete technical trigger (below 200-day MA) and a specific analyst action (hold to hold c-). No new earnings or guidance is introduced beyond previously reported results and a scheduled dividend date.

Market effects

BDC/credit-services names may see mild read-across if technical weakness and rating downgrades persist in small-cap credit lenders.

No specific regional catalyst beyond US small-cap trading.

Limited global relevance; story is company-specific and technical/analyst-driven.

Counterpoint

The downgrade is only from “hold (c)” to “hold (c-)” and LOAN still shows positive profitability metrics (net margin, ROE), so selling pressure may be overdone.

Key entities

  • Manhattan Bridge Capital, Inc

    Subject of the article; LOAN shares moved below the 200-day moving average and were downgraded by Weiss Ratings.

  • Weiss Ratings

    Downgraded LOAN from hold (c) to hold (c-) on May 11.

Related articles

$SMCIMed

Super Micro Computer Landed $60 Billion in Orders Last Quarter, but Trades at Just $30

Super Micro Computer (SMCI) said it booked over $60B in new orders in its fiscal Q4 ended June 30, lifting backlog to a record. It guided FY2026 revenue near the low end of $11B to $12.5B and gross margins at 15% to 17%. The company also plans $7B equity financing for AI server orders, noting some orders may not be firm and citing an independent review tied to export control issues.

$CSCOMed

Cisco Stock Is Finally Pricing In A New Growth Story

Cisco raised full-year revenue and EPS guidance on May 13, 2026, citing AI infrastructure demand. Management expects about $9 billion in FY2026 AI orders from hyperscalers and cited 5 hyperscaler design wins in Q3. Cisco shares rose about 20% since, with product orders up 19% YoY excluding hyperscaler growth. Options imply 41% IV ahead of the next catalyst.

$RMDMed

Off Into Weekend, As Early Work Undone

ResMed (ASX:RMD) fell 8.29% on Friday and is 3.09% lower for the week after a strong run. The company reported a solid Q4, with FY26 revenue up 10% to $5.7b, gross Q4 margin 62.3%, FY EPS up 17% to $11.17, and a 10% dividend increase to $0.66. Morgan Stanley downgraded to Equal Weight and cut its price target, citing cooling growth and Philips’ potential US return in 2027.